| 3.09 0.1 (3.32%) | 04-26 14:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.77 |
1-year : | 3.94 |
| Resists | First : | 3.23 |
Second : | 3.38 |
| Pivot price | 3.17 |
|||
| Supports | First : | 2.99 |
Second : | 2.48 |
| MAs | MA(5) : | 3.11 |
MA(20) : | 3.15 |
| MA(100) : | 3.31 |
MA(250) : | 3.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 30 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 4.13 | Low : | 2.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OVID ] has closed above bottom band by 10.2%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.14 - 3.16 | 3.16 - 3.18 |
| Low: | 2.94 - 2.97 | 2.97 - 2.99 |
| Close: | 2.96 - 2.99 | 2.99 - 3.02 |
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Thu, 18 Apr 2024
We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth - Yahoo Finance
Sat, 13 Apr 2024
Ovid Therapeutics Inc. (NASDAQ:OVID) Short Interest Update - MarketBeat
Fri, 05 Apr 2024
Ovid stock gains on bullish view at Wedbush (NASDAQ:OVID) - Seeking Alpha
Thu, 04 Apr 2024
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference - GlobeNewswire
Wed, 27 Mar 2024
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus ... - Business Wire
Wed, 27 Mar 2024
Stakeholder Capitalism: Q&A with Meg Alexander, Chief Strategy Officer at Ovid Therapeutics (Part 2) - Pharmaceutical Executive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 71 (M) |
| Held by Insiders | 4.51e+007 (%) |
| Held by Institutions | 15.9 (%) |
| Shares Short | 3,650 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.871e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -13 % |
| Return on Assets (ttm) | 978.4 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 391690 % |
| Gross Profit (p.s.) | 298.4 |
| Sales Per Share | -68.95 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.7 |
| Dividend | 0 |
| Forward Dividend | 2.8e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|